Skip to content

ResMed RMD Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Eli Lilly logo
Eli LillyLLY
Inogen logo
InogenINGN
Inspire Medical Systems logo
Inspire Medical SystemsINSP
LivaNova logo
LivaNovaLIVN
Pulmonx Corporation logo
Pulmonx CorporationLUNG
AdaptHealth logo
AdaptHealthAHCO

Other financials

Income statement

See full
Revenue$1.4B+10.8%
Gross profit$891.0M+16.3%
Operating income$499.8M+17.3%
Net income$398.7M+9.2%
EPS (diluted)$2.74+10.5%

Balance sheet

See full
Cash & equivalents$1.7B+78.0%
Total debt$1.1B+29.8%
Total equity$6.5B+17.1%
Total assets$8.8B+16.1%

Cash flow

See full
Operating cash flow$554.1M-4.2%
CapEx$33.7M+61.8%
Free cash flow$520.5M-6.7%

Valuation

See full
Market cap$28.27B-19.1%
Enterprise value$27.71B-19.8%
P/E18.6×-6.3×
P/S5.1×-1.7×

Profitability

See full
Gross margin61.6%+2.8pp
Operating margin34.2%+2.1pp
Net margin27.4%+1.3pp
FCF margin31.7%+0.4pp

Returns & leverage

See full
Return on equity25.2%-0.6pp
Debt / equity0.2×0.0×
Current ratio-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ResMed's software and technology licenses, net?
ResMed (RMD) reported software and technology licenses, net of $210.73M in Q1 2026.
How has ResMed's software and technology licenses, net changed year-over-year?
ResMed's software and technology licenses, net increased by 20.7% year-over-year, from $174.63M to $210.73M.
What is the long-term trend for ResMed's software and technology licenses, net?
Over 4 years (2021 to 2025), ResMed's software and technology licenses, net has grown at a 3.7% compound annual growth rate (CAGR), from $160.92M to $185.84M.